To provide Biosimilar
products around the world.
We specialize in developing biosimilar drugs. By providing our biosimilars to the medical fraternity, we are committed to contribute to the society and people by subsidizing medical spending to reduce financial burden of patients; while maintaining highest product quality
YL Biologics Limited is a joint venture between Yoshindo Inc. (headquartered in Toyama, Japan) and Lupin Limited (headquartered in Mumbai, India).
- Pharmaceuticals and Medical Devices Agency accepts the filing for YLB113, a biosimilar product of anti-rheumatoid arthritis biopharmaceutical Enbrel ”read more” link to press release PDF.
- Lupin and Yoshindo’s JV - YL Biologics announces successful outcome of global Phase III study for Etanercept biosimilar in Rheumatoid Arthritis ”read more” link to press release PDF.
Corporate Headquarters: 12F, Hamacho Center Building2-31-1,
Nihonbashi Hamacho, Chuo-ku, Tokyo 103-0007